Interim Report January – June 2017

CONTINUED GROWTH AND PROGRESS IN DEVELOPMENT PROJECTS

SECOND QUARTER 2017 (APR - JUN)

 • Net sales of non-Durable goods in the quarter amounted to SEK 36.4 (29.8) million, corresponding to an increase of 22 percent in SEK. Sales of non-Durable goods increased by 16 percent in local currency. Net sales in the quarter amounted to SEK 37.0 (34.5) million, corresponding to an increase of 7 percent. The increase corresponds to 2 percent in local currency.
• Operating income before depreciation and amortization (EBITDA), excluding items affecting comparability, amounted to SEK 6.2 (6.9) million, corresponding to an EBITDA margin of 17 percent. Items affecting comparability of SEK 0.6 (2.2) million, related to the acquisition and integration of Vivoline, have been charged against the quarter. EBITDA amounted to SEK 5.7 (4.8) million, corresponding to an EBITDA margin of 15 percent.
• Operating income amounted to SEK 2.0 (1.7) million, after amortization and depreciation of SEK 3.7 (3.1) million was charged against the quarter.
• Net income amounted to SEK 1.1 (1.5) million, resulting in earnings per share of SEK 0.04 (0.07).
• Cash flow from operating activities was SEK 8.7 (8.1) million.
• Warm perfusion sales from non-durable goods (STEEN Solution™, products and services related to the use of the XPS™ and LS™*) accounted for 31 (32) percent of the total sales of non-Durable goods.
• Extraordinary general meeting was held on 10 April 2017 and it was decided to approve the board proposal of a new issue of up to 2 361 408 new shares, which will raise up to approximately SEK 181 million before issue costs. The Private Placement was fully subscribed by the Third Swedish National Pension Fund (AP3), , Norron, Swedbank Robur and the Fourth Swedish National Pension Fund (AP4).
• As a result of warrants being exercised, the number of shares and votes in XVIVO Perfusion AB (publ) has during June 2017 increased by 215,000 shares and votes. The share issue of 215,000 shares raised approximately SEK 13 million.

THE PERIOD 2017 (JAN - JUN)

 • Net sales of non-Durable goods in the period amounted to SEK 70.0 (58.8) million, corresponding to an increase of 19 percent in SEK. Sales of non-Durable goods increased by 13 percent in local currency. Net sales in the period amounted to SEK 74.5 (68.0) million, corresponding to an increase of 10 percent. The increase corresponds to 4 percent in local currency.
• Operating income before depreciation and amortization (EBITDA), excluding items affecting comparability, amounted to SEK 11.3 (14.2) million, corresponding to an EBITDA , excluding items affecting comparability, margin of 15 percent. Items affecting comparability of SEK 1.9 (4.6) million, related to the acquisition and integration of Vivoline, have been charged against the period. EBITDA amounted to SEK 9.4 (9.6) million, corresponding to an EBITDA margin of 13 percent.
• Operating income amounted to SEK 2.0 (3.4) million, after amortization and depreciation of SEK 7.4 (6.2) million was charged against the period.
• Net income amounted to SEK 1.0 (2.6) million, resulting in earnings per share of SEK 0.04 (0.12).
• Cash flow from operating activities was SEK 6.7 (13.3) million.
• Warm perfusion sales from non-durable goods (STEEN Solution™, products and services related to the use of the XPS™ and LS™*) accounted for 33 (31) percent of the total sales of non-Durable goods.
• Two XPS™ were sold during the period; one XPS™ to Australia and one XPS™ to the Netherlands. Both countries are new countries with an XPS™. At the end of the period 45 clinics had access to the XPS™ or LS™.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• Inclusion of all 220 (110 + 110) patients is now completed in the NOVEL study which is being carried out in the US on STEEN Solution™ and XPS™. This clinical study will form the basis of the company’s PMA (Pre-market Approval) application to the FDA. Approximately 40 percent of all lung transplantations in the world are done in the US and STEEN Solution™ and XPS™ have already been approved for sales in the US under an HDE (Humanitarian Device Exemption) approval.
• Recruitment completed for the PrimECC® study at Sahlgrenska University Hospital. The study intends to expand the clinical documentation for PrimECC® and included a total of 80 patients. Analysis of the results will now begin and the first publication from the study is calculated for the later part of 2017.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, July 14, 2017. Telephone UK: +44 (0) 203 139 4830 or USA: +1 718 873 9077 , enter code 20105534#.

April 25, 2017
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO 

* Vivoline’s EVLP machine. 

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act.  The information was submitted for publication, through the agency of the contact person set out above, at 08:30 am CET on July 14, 2017.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags: